Tag Archives: FDA approval

PARP inhibitors represent an important new class of anticancer agents that are having a major impact on ovarian cancer treatment. These drugs target vulnerabilities in DNA damage response and repair pathways especially in cancer cells that have defects in BRCA and related genes. In an important clinical development announced April 6, 2018, the FDA expanded […]